Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are Gram-negative gut bacteria, chiefly Escherichia coli and Klebsiella pneumoniae, that make enzymes capable of hydrolysing penicillins, most cephalosporins, and aztreonam. By inactivating these widely used beta-lactams, ESBL producers narrow oral and intravenous options for common infections such as urinary tract and bloodstream infections, making them a major multidrug-resistant pathogen group.

Definition

ESBL-producing Enterobacteriaceae are Enterobacteriaceae that produce beta-lactamase enzymes able to hydrolyse extended-spectrum (third-generation) cephalosporins, penicillins, and aztreonam, while typically remaining susceptible to inhibition by classical beta-lactamase inhibitors and to carbapenems.

Scope

The entry covers the enzymatic basis of extended-spectrum resistance, the spectrum of beta-lactams affected and those spared, the dominant enzyme families, and the clinical and epidemiologic importance of ESBL producers. It describes resistance mechanisms for reference and does not provide treatment selection or dosing guidance.

Core questions

• What distinguishes an extended-spectrum beta-lactamase from a narrow-spectrum beta-lactamase?
• Which beta-lactam agents are inactivated by ESBLs and which are typically spared?
• Which enzyme families and host species dominate ESBL epidemiology?

Key concepts

• Extended-spectrum beta-lactamase (ESBL)
• CTX-M, TEM, and SHV enzyme families
• Third-generation cephalosporin resistance
• Beta-lactamase inhibitor susceptibility
• Plasmid-mediated, transferable resistance
• Co-resistance to fluoroquinolones and aminoglycosides

Mechanisms

ESBLs are beta-lactamase enzymes, most often of the CTX-M, TEM, or SHV families, that have evolved an active site able to hydrolyse extended-spectrum cephalosporins, penicillins, and the monobactam aztreonam. They are usually encoded on plasmids that also carry resistance to other drug classes, so ESBL producers are frequently co-resistant to fluoroquinolones and aminoglycosides. The enzymes are classically inhibited in vitro by beta-lactamase inhibitors such as clavulanic acid, and the organisms generally retain susceptibility to carbapenems, which the enzymes do not efficiently hydrolyse. Because the determinants are plasmid-borne, they spread readily between strains and species.

Clinical relevance

ESBL-producing organisms cause urinary tract infections, intra-abdominal infections, and bloodstream infections in both healthcare and community settings, and their resistance to cephalosporins removes a mainstay class from consideration, contributing to reliance on carbapenems and to selection pressure for further resistance. This entry describes the resistance phenotype for educational reference and is not a basis for choosing therapy in an individual case.

Epidemiology

Once mainly hospital-associated and dominated by TEM- and SHV-type enzymes in Klebsiella, ESBL epidemiology shifted with the global rise of CTX-M enzymes, especially in Escherichia coli, including community-onset urinary and bloodstream infections. ESBL-producing Enterobacteriaceae feature prominently on international priority pathogen lists.

History

Extended-spectrum beta-lactamases were first described in the 1980s, soon after third-generation cephalosporins came into wide use, initially as TEM and SHV variants in hospital Klebsiella outbreaks. From around 2000 the CTX-M enzyme family expanded globally, shifting the burden toward community-onset Escherichia coli infection.

Debates

Are beta-lactam/beta-lactamase inhibitor combinations adequate alternatives to carbapenems for ESBL infections?

Whether agents such as piperacillin-tazobactam can spare carbapenems in serious ESBL infections has been debated, with concern that over-reliance on carbapenems drives further resistance; the balance is an active question in stewardship.

Seminal works

• paterson-2005
• tacconelli-2018

Frequently asked questions

Why are carbapenems often effective against ESBL-producing bacteria?

Extended-spectrum beta-lactamases efficiently hydrolyse penicillins and cephalosporins but not carbapenems, so carbapenems usually retain activity unless the organism has also acquired a separate carbapenemase.

Which bacteria most commonly produce ESBLs?

Escherichia coli and Klebsiella pneumoniae are the predominant ESBL producers, although the enzymes occur across the Enterobacteriaceae because the genes are carried on transferable plasmids.